Selected article for: "acute sign and long term outcome"

Author: Shi, Chenyu; Killingsworth, Murray C.; Bhaskar, Sonu Menachem Maimonides
Title: Prognostic capacity of hyperdense middle cerebral artery sign in anterior circulation acute ischaemic stroke patients receiving reperfusion therapy: a systematic review and meta-analysis
  • Cord-id: 25ow8q99
  • Document date: 2021_6_6
  • ID: 25ow8q99
    Snippet: Pre-intervention CT imaging-based biomarkers, such as hyperdense middle cerebral artery sign (HMCAS) may have a role in acute ischaemic stroke prognostication. However, the clinical utility of HMCAS in settings of reperfusion therapy and the level of prognostic association is still unclear. This systematic review and meta-analysis investigated the association of HMCAS sign with clinical outcomes and its prognostic capacity in acute ischaemic stroke patients treated with reperfusion therapy. Pros
    Document: Pre-intervention CT imaging-based biomarkers, such as hyperdense middle cerebral artery sign (HMCAS) may have a role in acute ischaemic stroke prognostication. However, the clinical utility of HMCAS in settings of reperfusion therapy and the level of prognostic association is still unclear. This systematic review and meta-analysis investigated the association of HMCAS sign with clinical outcomes and its prognostic capacity in acute ischaemic stroke patients treated with reperfusion therapy. Prospective and retrospective studies from the following databases were retrieved from EMBASE, MEDLINE and Cochrane. Association of HMCAS with functional outcome, symptomatic intracerebral haemorrhage (sICH) and mortality were investigated. The random effect model was used to calculate the risk ratio (RR). Subgroup analyses were performed for subgroups of patients receiving thrombolysis (tPA), mechanical thrombectomy (EVT) and/or combined therapy (tPA + EVT). HMCAS significantly increased the rate of poor functional outcome by 1.43-fold in patients (RR 1.43; 95% CI 1.30–1.57; p < 0.0001) without any significant differences in sICH rates (RR 0.91; 95% CI 0.68–1.23; p = 0.546) and mortality (RR 1.34; 95% CI 0.72–2.51; p = 354) in patients with positive HMCAS as compared to negative HMCAS. In subgroup analyses, significant association between HMCAS and 90 days functional outcome was observed in patients receiving tPA (RR 1.53; 95% CI 1.40–1.67; p < 0.0001) or both therapies (RR 1.40; 95% CI 1.08–1.80; p = 0.010). This meta-analysis demonstrated that pre-treatment HMCAS increases risk of poor functional outcomes. However, its prognostic sensitivity and specificity in predicting long-term functional outcome, mortality and sICH after reperfusion therapy is poor. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13760-021-01720-3.

    Search related documents:
    Co phrase search for related documents
    • absence presence and acute ischaemic stroke: 1
    • absence presence and acute stroke: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • absence presence and low resource: 1
    • abstract title and acute ischaemic stroke: 1
    • abstract title and acute ischaemic stroke treatment: 1
    • abstract title and acute stroke: 1
    • abstract title and low heterogeneity: 1, 2
    • abstract title and low resource: 1, 2, 3
    • accurate relationship and low heterogeneity: 1
    • acute ischaemic stroke and long term functional outcome: 1
    • acute ischaemic stroke and low heterogeneity: 1
    • acute stroke and location association: 1, 2
    • acute stroke and long term functional outcome: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute stroke and low heterogeneity: 1, 2
    • acute stroke and low resource: 1
    • acute stroke and low resource setting: 1
    • additional limit and low resource: 1